Sequent Scientific Limited has informed the Exchange about Investor Presentation
Proven Ability In Life Sciences
November 17, 2025
To,
National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051
Scrip code: SEQUENT
Subject: Revised Investor Presentation for Q2 FY 2025-26
Dear Sir/ Madam,
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith revised Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025.
This is for your information and appropriate dissemination.
Thanking you,
Yours faithfully, For Sequent Scientific Limited
Yoshita Vora Company Secretary & Compliance Officer Encl: A/a
Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana
Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra
SeQuent Scientific Limited
Tel No.: +91 9391139986 / 22-4111 4777 I CIN: L99999TS1985PLC196357 Website: http://www.sequent.in I Email Id: investorrelations@sequent.in
INVESTOR PRESENTATION Q2 FY26
S E Q U E N T S C I E N T I F I C L I M I T E D
14th Nov 2025
Steadfast commitment to improvement in business fundamentals
“The results of Q4 FY 25-26 and first half FY 25-26 reinforce the transformational journey
undertaken by the company. Revenue, margins and profits have continued to show healthy
growth on the back of new product introductions, superior product mix and cost
improvement programs. The merger with Viyash Life Sciences is almost concluded. We are
already seeing the benefits in manufacturing synergies, R&D programs and customer leads.
Viyash continues to deliver market beating performance in new filings, sales and margins.
The merged entity is now well positioned to build new revenue streams, in addition to
accelerating growth of existing businesses.”
Rajaram Narayanan Sequent Scientific Limited
Dr Hari Babu Bodepudi Viyash Life Sciences Limited
Sequent + Viyash : Combined Q2 FY26 Performance Highlights
Revenues
EBITDA1
EBITDA margin
All values in ₹ Mn
Net Debt to LTM EBITDA1
₹8,521 Million
₹1,890 Million
22.2%
0.7x
+16 % YoY
+76% YoY
+750 bps YoY
1.4x in Q2 FY25
Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers
3
Sequent + Viyash : Combined H1 FY26 Performance Highlights
Revenues
EBITDA1
EBITDA margin
All values in ₹ Mn
Net Debt to LTM EBITDA1
₹16,462 Million
₹3,180 Million
19.3%
0.7x
+12.5 % YoY
+48 % YoY
+460 bps YoY
1.4x in H1 FY25
Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers
4
SeQuent Q2FY26 Performance Update
Sequent: Strong profitable business growth continues in Q2FY26
All values in ₹ Mn
Revenues Revenues
EBITDA1 EBITDA1
EBITDA1 margin
PAT
₹4,240 ₹4,240 Million Million
+15.0% YoY
₹657 ₹657 Million Million
+47.0% YoY
15.5%
₹ 196 Million
+330 bps YoY
+200% YoY
1. EBITDA Adjustment for ESOP and foreign currency fluctuation
6
Sequent: Strong profitable business growth continues in H1 FY26
All values in ₹ Mn
Revenues Revenues
EBITDA1 EBITDA1
EBITDA1 margin
PAT
₹8,654 ₹4,240 Million Million
₹1,259 ₹657 Million Million
14.5%
₹ 372 Million
+14.0% YoY
+35.4 % YoY
+220 bps YoY
+140 % YoY
1. EBITDA Adjustment for ESOP and foreign currency fluctuation
7
Sequent : Broad based revenue growth across all businesses
All values in ₹ Mn
Revenue Distribution
Q2 FY26
Q2 FY25
YoY Gr% Q1 FY26 QnQ Gr% H1 FY26
H1 FY25
YoY Gr%
Formulations
Europe
Emerging Markets
India
APIs
Other Sales
Global Sales
One Offs #
3,351
1,520
1,469
362
830
27
2,836
1,335
1,160
341
773
22
4,207
3,631
18%
14%
27%
6%
7%
20%
16%
13
43
-1%
-7%
-1%
38%
-21%
82%
-5%
3,383
1,640
1,480
263
1,054
15
4,451
(56)
19
6,734
3,159
2,949
625
1,884
41
5,837
2,910
2,342
585
1,697
64
8,659
7,598
(56)
51
(74)
64
15%
9%
26%
7%
11%
-35%
14%
Adjustment* - Ind AS 29*
33
Reported Sales
4,240
3,686
15%
4,414
-4%
8,654
7,589
14%
*Adjustment on account of hyperinflation in Turkey as per Ind AS 29
# Provision for customer claim on shipments in prior years
8
SeQuent: Q2FY26 Business Performance
All values in ₹ Mn
Formulations
Europe: Significant growth in Spain with good exports performance
Emerging Markets:
▪ Launched Tulaject in Brazil & received MA for Mexico market ▪ R&D infrastructure expanded
India: Business beginning to accelerate as field team expansion ramps up
Business momentum continues, ~7% YoY growth
Launched a product for the US market
API
Completed successful audits for large customers
SRL USFDA audit completed – EIR awaited
1,000+ FDFs
90+ Countries
5 Manufacturing Facilities
35 APIs
50+ Countries
2 Manufacturing facilities
Sequent Consolidated Financials
Particulars
Revenue from Operations Material Consumption Gross Margin % Employee Benefit Expenses Operating Expenses EBITDA1 % ESOP cost Exceptional Items IndAS 29 Adjustment Exchange Gain / (Loss) Other Income Finance Cost Depreciation Earnings Before Tax Taxes Earnings After Tax
Q2 FY26 4,240 (2,131) 2,109 49.7% (731) (721) 657 15.5% (86) (17) (7) (7) 22 (135) (155) 272 (76) 196
Q2 FY25 3,686 (1,953) 1,734 47.0% (603) (683) 447 12.1% (67) (43) 25 (14) 45 (143) (171) 79 (16) 63
Grw YoY % 15.0%
21.6%
21.2% 5.5% 47.0%
243.7%
209.4%
Q1 FY26 4,414 (2,345) 2,069 46.9% (677) (789) 602 13.6% (114) (13) 37 (4) 39 (142) (151) 255 (80) 176
Grw QnQ % -3.9%
1.9%
7.9% -8.7% 9.1%
6.5%
11.6%
All values in ₹ Mn
H1 FY26 8,654 (4,477) 4,178 48.3% (1,408) (1,510) 1,259 14.5% (199) (29) 30 (10) 60 (277) (306) 527 (155) 372
H1 FY25 7,589 (4,096) 3,493 46.0% (1,183) (1,380) 930 12.3% (108) (43) 17 (28) 72 (307) (333) 199 (45) 154
Grw YoY % 14.0%
19.6%
19.1% 9.4% 35.4%
164.6%
141.3%
1. EBITDA Adjustment for ESOP and foreign currency fluctuation
Viyash: Business Update
Viyash: Q2FY26 Business Performance
Revenues
EBITDA1
EBITDA1 margin
PAT
₹4,281 Million
₹1,233 Million
17.8% YoY
96% YoY
28.8%
1149 bps YoY
Note: 1. Viyash EBITDA is adjusted for ESOP costs
₹533 Million
Q2 FY25 Loss (82mn)
12
Viyash: Q2 FY26 Key growth drivers
New product launches
Focus on CDMO business
Improved product mix
Network optimisation for better efficiencies
Backward and Forward integration
13
Viyash: H1FY26 Business Performance
Revenues
EBITDA1
EBITDA1 margin
PAT
₹7,808 Million
₹1,921 Million
11.0% YoY
58.9% YoY
24.6%
741 bps YoY
Note: 1. Viyash EBITDA is adjusted for ESOP costs
₹726 Million
H1 FY25 Loss (94mn)
14
Viyash Financial Performance
All values in ₹ Mn
Particulars
Revenue from Operations Material Consumption Gross Margin % Employee Benefit Expenses Operating Expenses Exchange Gain/(Loss) EBITDA(1) % ESOP Cost Exceptional Items (1) Other Income Finance Cost Depreciation & Amortisation Amortization of Acquisition Intangibles Earnings Before Tax Taxes Earnings After Tax
Grw YoY% 18% 3% 30%
-6% 10%
96% 11% -93%
Q2 Q2 FY25 FY26 4,281 3,632 (1,667) (1,625) 2,008 2,614 61.1% 55.3% (598) (561) (798) (875) 17 55 1,233 629 28.8% 17.3% (189) (29) 61 (65) (174)
(14) - 10 (40) (191)
(245)
(236)
752 (219) 533
(2) (80) (82)
Grw
-3% 11%
21% 13% 28%
Q1 FY26 QnQ % 3,527 (1,480) 2,047 58.0% (581) (788) 10 688 19.5% (16) - 23 (63) (164)
-14%
79%
(241)
228 (35) 193
H1 H1 FY25 FY26 7,808 7,032 (3,147) (3,204) 3,828 4,661 59.7% 54.4% (1,142) (1,192) (1,663) (1,454)
26 66 1,921 1,209 24.6% 17.2% (218) (58) 88 (144) (353)
(30) - 33 (103) (355)
FY 25
Grw YoY 11% 14,580 -2% (6,608) 7,971 22% 54.7% -4% (2,471) 14% (3,018)
59%
-86%
65 2,546 17.5% (237) (824) 182 (256) (720)
(486)
(469)
(1,003)
980 (254) 726
54 (148) (94)
(311) 146 (165)
o Healthy revenue growth. Q2FY26 revenue grew by 18% YoY. H1FY26 YoY growth of 11%
o Gross Margin improved to 61.1% in Q2FY26 from 54.7% in FY25 and 58% in Q1FY26
o EBITDA % improved to 28.8% in Q2
FY26 from 17.5 % in FY25 and 19.5% in Q1FY26
o Significant improvement in profit
before tax, profit after tax.
Note: 1. EBITDA for Viyash is before ESOP costs, cost for accelerated vesting of warrants and exceptional items (call option charge, merger expenses and provision for contractual one-time bonus)
15
Key updates from Q2 FY26
Facility Inspections
4 Regulatory Audits 56 Customer audits 1 US FDA EIR
Regulatory Approvals
Launches
2APIs: (USDMF-1 ; EDQM-1
2 FDFs (US) 2 APIs
Products Filed
Validations Completed
R&D Pipeline
9 Filings – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1) FDFs -Nil
Source: Viyash Life Sciences website published Investor Presentation
3 APIs
16+ Products
16
Merger Update
Q2FY26: Combined business performance
Q2 FY26 (For the quarter)
Revenue (INR Mn)
EBITDA1 (INR Mn)
SeQuent
Combined
YoY Growth % (Combined)
4,281
4,240
8,521
16.3%
1,233
657
1,890
76%
EBITDA Margin %
28.8%
15.5%
22.2%
+750 bps
Net Debt to LTM EBITDA
0.08x
1.7x
0.7x
Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers
18
Combined P&L – Snapshot
Particulars
Revenue from Operations Material Consumption Gross Margin % Operating Expenses Operating Exchange Gain / (Loss) EBITDA3 % ESOP cost Exceptional Items1 Ind AS 29 Adjustment Exchange Gain / (Loss) Other Income Finance Cost D&A Amortization of Acquisition Intangibles Profit Before Tax Taxes Profit After Tax Adjusted PAT2
Viyash
SeQuent
Combined
FY25 14,580 (6,608) 7,971 54.7% (5,490) 65 2,546 17.5% (82) (979)
182 (256) (720) (1,003) (311) 146 (165) 1,296
H1 FY26 7,808 (3,147) 4,661 59.7% (2,806) 66 1,921 24.6% (30)
33 (103) (355) (486) 980 (254) 726 1,083
FY25 15,514 (8,119) 7,395 47.7% (5,402)
1,993 12.8% (324) (50) 29 (80) 147 (608) (589) (76) 443 (120) 322 429
H1 FY26 8,654 (4,477) 4,178 46.9% (2,919)
1,259 14.5% (199) (29) 30 (10) 60 (277) (272) (34) 527 (155) 372 416
FY25 30,094 (14,727) 15,367 51.1% (10,892) 65 4,540 15.1% (406) (1,029) 29 (80) 329 (864) (1,309) (1,079) 131 26 157 1,725
H1 FY26 16,462 (7,624) 8,838 53.7% (5,724) 66 3,180 19.3% (230) (29) 30 (10) 93 (379) (627) (520) 1,507 (410) 1,098 1,499
Key Notes :
ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events: - Exceptional Items include cost of
accelerated vesting for share warrants, call option charge, merger expenses and provision for a contractual one-time bonus payable at Viyash
- Amortization of acquisition intangibles in
Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27
Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash) PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax) Adjusted for ESOP costs
1. 2. 3. Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers
19
Merger – Process Update
Merger process status update
• CCI approval and Stock Exchange clearance
received
• NCLT approval order reserved on Oct 31, 2025;
pronouncement expected soon
• Focus on synergy realization for next 12 months • The process is well on track as per estimated
timelines
20
Synergy Update
Area
R&D
Key Ideation Action Items
Progress
• R&D teams to be co-located; to work
collaboratively on NPD & cost improvement
• QA & Testing to be moved on-site from 3rd
party location
API R&D fully integrated leading to accelerated development • 4 New animal health products
developed/validated
• 3 Cost improvement projects completed
Regulatory filing in progress
Manufacturing
• Utilize available low-cost capacity through
the group; action plan created • Procurement synergies identified
Sales
Others
• Leverage key relationships of both
companies; outreach & discussion plan prepared
• Assess shared administrative & support
functions
• 6 Intermediates validated at Viyash sites,
which were procured from external sources
• New production block created in short
time to improve capacity, productivity and cost of Sequent products.
• One large volume Sequent API validated
& filing under progress
Business teams working closely to identify opportunities to cross sell
All support functions integration initiated
21
New production block commissioned in record time
New production block created in short time to improve capacity, productivity and cost of Sequent products
One large volume Sequent API validated & filing under progress
22
For details, feel free to contact:
Yoshita Vora
Company Secretary
Abhishek Singhal
Investor Relations Consultant
+91 22 4111 4777
abhishek@arunya.co.in
investorrelations@sequent.in
Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39,
Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana
Websites: www.sequent.in, www.alivira.co | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: SEQUENT
ISIN: INE807F01027
Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
23
Thank You